1. Flemming Rasmussen Flemming Rasmussen Canada says:

    I read through the NCI's recent Blue Ribbon Panel Report and agree the moonshot's flight plan has significant risks that may preclude it from reaching its destination.  

    Rhetoric aside, the BRP and the focus in this article have a niche thrust.  For instance, why are chemists and biologists either not mentioned or not even a part of your team.  The cancer effort hasn't committed to understanding how our underlying chemistry underpins every one of the niche areas of study you mention....and nothing in the BRP plan nor yours speaks to to addressing this.

    Precision medicine is a fancy term, one of the better ones of recent years.  Views of what it brings to the table vary immensely; the jury is out on whether this can be achieved with less drugs and much improved patient outcomes at a fraction of the present cost

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.